{"organizations": [], "uuid": "53cd9e08b80f9b0a65f4b230c9a8bbe08887dbc2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-spectrum-pharmaceuticals-announces/brief-spectrum-pharmaceuticals-announces-rolontis-met-the-primary-endpoint-in-the-phase-3-advance-study-idUSFWN1PV0SZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T14:15:00.000+02:00", "replies_count": 0, "uuid": "53cd9e08b80f9b0a65f4b230c9a8bbe08887dbc2"}, "author": "", "url": "https://www.reuters.com/article/brief-spectrum-pharmaceuticals-announces/brief-spectrum-pharmaceuticals-announces-rolontis-met-the-primary-endpoint-in-the-phase-3-advance-study-idUSFWN1PV0SZ", "ord_in_thread": 0, "title": "BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "advance study reuters", "sentiment": "none"}, {"name": "reuters) - spectrum pharmaceuticals inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 17 PM / in 7 minutes BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study Reuters Staff \nFeb 5 (Reuters) - Spectrum Pharmaceuticals Inc: \n* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISâ„¢ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY \n* SPECTRUM PHARMACEUTICALS INC - ADVANCE STUDY MET PRIMARY EFFICACY ENDPOINT \n* SPECTRUM PHARMACEUTICALS - PLANS TO FILE BLA FOR RECOVER PHASE 3 STUDY IN Q4 THIS YEAR Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-05T14:15:00.000+02:00", "crawled": "2018-02-05T14:32:38.002+02:00", "highlightTitle": ""}